MedTrace Logo

To Assess the Safety, Tolerability and Pharmacokinetics of AZD2820 After Single Ascending Doses

NCT01332214 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2011-11-21

No results posted yet for this study

Summary

This is a randomised, single-blind, placebo-controlled Phase I study to investigate the safety, tolerability and pharmacokinetics after administration of single doses of AZD2820 to healthy male subjects.

Conditions

  • Healthy

Interventions

DRUG

AZD2820

Subcutaneous Injection in abdomen or Thigh

DRUG

Placebo

Subcutaneous Injection in abdomen or Thigh

Sponsors & Collaborators

Principal Investigators

  • Mirjana Kujacic, PhD · AstraZeneca

  • Prof J Ritter BM BCh, MRCP, FRCP · Quintiles, Inc.

  • Mark Berner Hansen, PhD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01332214 on ClinicalTrials.gov